IRESSA as a first-line treatment for EGFR mutation-positive advanced NSCLC

IRESSA is an oral monotherapy treatment which offers superior progression-free survival, better tolerability and quality of life compared with doublet chemotherapy (carboplatin/paclitaxel) as first-line treatment for EGFR mutation-positive advanced NSCLC.1

IRESSA has proven tolerability benefits compared with doublet chemotherapy, with convenient oral once-daily dosing, better quality of life and symptom control for the patient.

On the 1st July 2009 the European Commission granted marketing authorisation for IRESSA for the treatment of adults with locally advanced or metastatic NSCLC with activating mutations of EGFR-TK across all lines of therapy. This authorisation is based on a data package including two pivotal phase III studies comparing IRESSA with chemotherapy, IPASS and INTEREST.

References

1. Mok TS et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New Engl J Med 2009; 361: 947-957.